GEN2 is well tolerated with minimal toxicity and signs of pharmacodynamic activity in an ongoing Phase 1 dose escalation and ...

NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) announced today that the U.S. Food and Drug Administration has accepted for review the Biologics License ...

CLEVELAND, May 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results and business highlights for the first quarter of 2025 and shared recent operational ...

Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced that Maria Törnsén has been appointed Chief Operating Officer (COO) and President ...

Hansa communicated the results from the 15-HMedIdeS-09 study in December 2024. Professor Shahram Attarian, Head of Department of Neuromuscular Diseases and ALS, Hopitaux Universitaires de Marseille ...

NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of ...

Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), will present data from its 15-HMedIdeS-09 Phase 2 single arm study of imlifidase, a first in ...

They weren’t snakes, of course, but nematodes, also known as roundworms—and, it turns out, they’re the most common ...

Here's our list of the leaders in Massachusetts tech, biotech and climate tech who aren't just surviving, but moving their ...

A baby born with a rare and dangerous genetic disease is thriving after getting an experimental gene editing treatment made ...

The researchers described the unprecedented speed of the oversight steps as being "through alternative procedures." In month ...

In a historic medical breakthrough, a child diagnosed with a rare genetic disorder has been successfully treated with a customized CRISPR gene editing therapy by a team at Children's Hospital of ...